3-(E-3-甲氧基-3-氧代-1-丙烯-1-基)苯基硼酸 | 380430-59-1

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 中文名称: 3-(E-3-甲氧基-3-氧代-1-丙烯-1-基)苯基硼酸
• 中文别名: [3-(E-3-甲氧基-3-氧代-1-丙烯-1-基)苯基]硼酸
• 英文名称: [3-((E)-3-methoxy-3-oxo-1-propen-1-yl)phenyl]boronic acid
• 英文别名: 3-(3-methoxy-3-oxo-1-propen-1-yl)phenyl boronic acid；(3-(3-Methoxy-3-oxoprop-1-en-1-yl)phenyl)boronic acid；[3-[(E)-3-methoxy-3-oxoprop-1-enyl]phenyl]boronic acid
• CAS: 380430-59-1
• 化学式: C₁₀H₁₁BO₄
• 分子量: 206.006
• InChiKey: DZTWTEGVKAHSGN-AATRIKPKSA-N

物化性质

• 熔点：
  126-130
• 沸点：
  406.1±47.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.45
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2931900090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
3-(E-3-Methoxy-3-oxo-1-propen-1-yl)phenylboronic acid
Product Name:
Synonyms: Methyl 3-boronocinnamate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
3-(E-3-Methoxy-3-oxo-1-propen-1-yl)phenylboronic acid
Ingredient name:
CAS number: 380430-59-1

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C10H11BO4
Molecular weight: 206.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(E-3-甲氧基-3-氧代-1-丙烯-1-基)苯基硼酸 、 2-morpholin-4-yl-4-oxo-4H-chromen-8-yl trifluoromethanesulfonate 在 四(三苯基膦)钯 、 potassium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 反应 18.0h， 以17%的产率得到3-[3-(2-morpholin-4-yl-4-oxo-4H-chromen-8-yl)phenyl]acrylic acid methyl ester
  参考文献：
  名称：

  Discovery of Potent Chromen-4-one Inhibitors of the DNA-Dependent Protein Kinase (DNA-PK) Using a Small-Molecule Library Approach

  摘要：

  Structure-activity relationships for inhibition of DNA-dependent protein kinase (DNA-PK) have been defined for substituted chromen-4-ones. For the 2-amino-substituted benzo[h]chromen-4-ones, a morpholine substituent at this position was essential for activity. Small libraries of 6- and 7-alkoxy-substituted chromen-4-ones showed that a number of 7-alkoxysubstituted chromenones displayed improved activity. Focused libraries incorporating 6-, 7-, and 8-aryl and heteroaryl substituents were prepared. In these cases, 6- and 7-substitution was disfavored, whereas 8-substitution was largely tolerated. Surprisingly, two compounds, 2-N-morpholino-8-dibenzofuranyl-chromen-4-one (NU7427, 32{38}) and the 2-N-morpholino-8-dibenzothiophenyl-chromen-4-one (NU7441, 32{26}) were excellent inhibitors (IC50 vs DNAPK = 40 and 13 nM, respectively). The ring-saturated analogue 2-N-morpholino-8-(6',7',8',9'-tetrahydrodibenzothiophene)chromen-4-one, 36, retained potent activity (IC50 vs DNA-PK = 23 nM). The dibenzothiophene 32{38} sensitized HeLa cells to ionizing radiation in vitro, with dose modification factors of 2.5 at 10% survival being observed at 0.5 mu M. The cytotoxicity of the topoisomerase II inhibitor etoposide was also potentiated.

  DOI：

  10.1021/jm050444b

文献信息

• [EN] PHENETHANOLAMINE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES<br/>[FR] DERIVES DE PHENETHANOLAMINE PERMETTANT DE TRAITER DES MALADIES DES VOIES RESPIRATOIRES
  申请人：GLAXO GROUP LTD

  公开号：WO2004039762A1

  公开（公告）日：2004-05-13

  The present invention relates to novel compounds of formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.

  本发明涉及式（I）的新化合物，以及制备它们的方法，含有它们的药物组合物，以及它们在治疗中的应用，特别是在预防和治疗呼吸道疾病中的应用。
• PYRAZINE COMPOUNDS, THEIR USE AND METHODS OF PREPARATION
  申请人：Mao Wang

  公开号：US20100210627A1

  公开（公告）日：2010-08-19

  The invention provides compounds according to formula (I) their use and methods for preparation wherein A, X, Y, R1, R2 and R3 are defined herein. The compounds of the invention inhibit specific serine/threonine kinases involved in inflammatory processes and aberrant cell proliferation, and are thus useful for treating associated diseases and pathological conditions such as Pim kinase-mediated diseases and pathological conditions involving inflammation, including Chron's disease, inflammatory bowel disease, rheumatoid arthritis, and chronic inflammatory disease, or aberrant cell proliferation including various cancers.

  该发明提供了根据式(I)的化合物及其用途和制备方法，其中A、X、Y、R1、R2和R3在此处被定义。该发明的化合物抑制参与炎症过程和异常细胞增殖的特定丝氨酸/苏氨酸激酶，因此可用于治疗相关疾病和病理条件，如Pim激酶介导的疾病和涉及炎症的病理条件，包括克罗恩病、炎性肠病、类风湿关节炎和慢性炎症性疾病，或异常细胞增殖，包括各种癌症。
• [EN] SELECTIVE ROCK2 KINASE INHIBITOR<br/>[FR] INHIBITEUR SÉLECTIF DE KINASE ROCK2<br/>[ZH] 选择性ROCK2激酶抑制剂
  申请人：HANGZHOU BANGSHUN PHARMACEUTICAL CO LTD

  公开号：WO2022042666A1

  公开（公告）日：2022-03-03

  提供了一种通式(I)所示的ROCK2激酶抑制剂及其在制备预防和/或治疗与ROCK2相关障碍的疾病的药物中的用途。所述化合物是高效选择性ROCK2激酶抑制剂，可用于治疗和/或预防肺纤维化、肝纤维化、肾纤维化、心脏纤维化或非酒精性脂肪性肝炎等疾病。
• Modulators Of Nuclear Receptors
  申请人：Bayne Christopher D.

  公开号：US20080119488A1

  公开（公告）日：2008-05-22

  Compounds of the invention, such as compounds of formula (I), where n, m, A, R1, R2, R3, R4 and R5 are defined herein, are useful as modulators of the activity of liver X receptors. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.

  本发明的化合物，例如式（I）中的化合物，其中n，m，A，R1，R2，R3，R4和R5在此定义，可用作肝X受体活性调节剂。还公开了含有该化合物的制药组合物和使用该化合物的方法。
• Pyrazine compounds, their use and methods of preparation
  申请人：Boehringer Ingelheim International GmbH

  公开号：US08318723B2

  公开（公告）日：2012-11-27

  The invention provides compounds according to formula (I) their use and methods for preparation wherein A, X, Y, R1, R2 and R3 are defined herein. The compounds of the invention inhibit specific serine/threonine kinases involved in inflammatory processes and aberrant cell proliferation, and are thus useful for treating associated diseases and pathological conditions such as Pim kinase-mediated diseases and pathological conditions involving inflammation, including Chron's disease, inflammatory bowel disease, rheumatoid arthritis, and chronic inflammatory disease, or aberrant cell proliferation including various cancers.

  本发明提供了按照式（I）定义的化合物，它们的用途和制备方法，其中A、X、Y、R1、R2和R3在此定义。本发明的化合物抑制特定的丝氨酸/苏氨酸激酶，参与炎症过程和异常细胞增殖，并因此有用于治疗相关疾病和病理条件，如Pim激酶介导的疾病和涉及炎症的病理条件，包括克罗恩病、炎症性肠病、类风湿性关节炎和慢性炎症性疾病，或包括各种癌症的异常细胞增殖。